Dall’Oglio F, Puviani M, Milani M, et al. - Researchers conducted this pilot, prospective, two‐center, assessor‐blinded study to assess the effectiveness and the tolerability of E‐AR cream in patients with mild to moderate rosacea treated for 8 weeks. The key findings were the Investigator Global Assessment (IGA) 7‐point score (from 0, completely clear; to 6, severe) and the clinical and instrumental erythema severity score (ESS) (from 0 to 4) assessed in a blinded fashion (randomly coded photographs) at baseline, after 4 (only clinical) and 8 weeks (clinical and instrumental). Thirty individuals (22 women and 8 men; mean age 38 years) were recruited after their written informed consent. In mild to moderate rosacea patients, this new GSH‐C4, beta‐glycyrrethic and azelaic acids cream has shown to be efficacious. The local tolerability is in line with other treatments for anti-rosacea.